Fig. 3. Treatment with ABT-199 (venetoclax) or MCL1 inhibitor A-1210477 induces apoptosis of AML cells.

a OCI-AML5, MV4-11, MOLM13, and SKM1 cells were treated with the indicated concentrations of ABT-199 for 48 h. Then, the % of annexin V-positive, apoptotic cells were determined by flow cytometry. Columns, mean of three experiments; Bars, Standard error of the mean. b MOLM13 and MV4-11 cells were treated with the indicated concentrations of ABT-199 for 24 h. Total cell lysates were prepared and immunoblot analysis was conducted. The expression levels of β-Actin in the cell lysates served as the loading control. The numbers beneath the bands represent densitometry analysis. c MOLM13 and OCI-AML5 cells were treated with the indicated concentrations of ABT-199 for 16 h. Cells were fixed, permeabilized and stained with Alexa488-conjugated BAX (6A7) antibody followed by flow cytometry. Values represent fold induction of active BAX over control cells. d OCI-AML5, MV4-11, MOLM13, and SKM1 cells were treated with the indicated concentrations of the MCL1-specific inhibitor, A-1210477 for 48 h. The % of annexin V-positive, apoptotic cells were determined by flow cytometry. Columns, mean of three experiments; Bars, Standard error of the mean